EGFR and lung carcinoma: Treatment of A549 and H460 (EGFR wild-type) and H1650 and H1975 (EGFR mutant) lung cancer cell lines with three different CK2 inhibitors (4,5,6,7-tetrabromo-1H-benzotriazole (TBB), tetrabromocinnamic acid (TBCA), and hematein) resulted in reduced STAT3 activation, growth suppression, and enhanced radiosensitivity [102].